CHICAGO–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the pivotal Phase III CLL14 study in previously untreated chronic lymphocytic leukemia (CLL) showing that Venclexta® (venetoclax) plus Gazyva® (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival (PFS). The 12-month, fixed-duration, chemotherapy-free combination reduced the risk of disease worsening or death by 65 percent compared to G http://www.businesswire.com/news/home/20190604005794/en/Pivotal-Phase-III-CLL14-Results-Venclexta-Combination/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
Home What's New PR Newswire Events Pivotal Phase III CLL14 Results for Venclexta in Combination with Gazyva for...